Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Becton, Dickinson and Company    BDX

BECTON, DICKINSON AND COMPANY (BDX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Becton Dickinson's 1st-Quarter Earnings Surge; Raises Year-View

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2013 | 12:50pm CET
   By Saabira Chaudhuri 
 

Becton Dickinson & Co.'s (>> Becton, Dickinson and Co.) fiscal first-quarter earnings more than doubled as the medical device maker recorded revenue growth across all its segments, while margins also widened.

For the current year, Becton raised the bottom end of its revenue guidance, now expecting foreign currency neutral revenue growth starting at 4% versus its prior view starting at 3.5%. It now expects per-share earnings from continuing operations between $5.69 and $5.72, up from its prior view of earnings between $5.58 and $5.64.

The maker of products like surgical blades and test kits last spring struck a deal to sell the bulk of its lab-products business to Corning Inc. (>> Corning Incorporated) for $730 million in cash. Analysts who follow the company noted the sale stripped Becton Dickinson of a cash cow yet also gave it the freedom to focus on businesses with higher growth potential.

Ahead of the company's earnings announcement, analysts at Mizuho Securities downgraded Becton's ratings, noting that the company's life science research business--which makes up about 15% of sales--has been a drag on results for the past year, adding that they see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish.

Still, Chief Executive Vincent A. Forlenza on Tuesday said the company is "starting to see notable results," adding that Becton is "growing revenues across our three segments, driving margin expansion and delivering a higher quality of earnings."

For the quarter ended Dec. 31, Becton Dickinson reported a profit of $625.4 million, or $3.13 a share, compared with $263 million, or $1.21 a share, a year earlier. Per-share earnings from continuing operations were $1.35 versus $1.14.

Revenue increased 3.7% to $1.9 billion. Analysts polled by Thomson Reuters most recently forecast earnings of $1.24 a share on revenue of $1.86 billion.

Gross margin widened to 52.9% from 50.8%.

Becton Dickinson's sales grew 3% in the U.S. and 4.3% internationally. The company's medical unit, its largest by revenue, reported sales rose 3.5%. The diagnostics business posted revenue growth 5%, while bioscience revenue was up 1.7%.

Shares closed Monday at $85.16 and were inactive premarket. The stock has risen 11% in the past three months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Becton, Dickinson and Co., Corning Incorporated
Stocks mentioned in the article
ChangeLast1st jan.
BECTON, DICKINSON AND COMPANY 0.93% 220.34 Delayed Quote.2.17%
CORNING 0.31% 29.3 Delayed Quote.-8.53%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BECTON, DICKINSON AND COMP
02/23RED HAT : U.S. Patents Awarded to Inventors in Utah (Feb. 23)
AQ
02/23BECTON, DICKINSON AND COMPANY (NYSE : BDX) Files An 8-K Creation of a Direct Fin..
AQ
02/20BECTON DICKINSON AND : BD Launches Circulating Cell-Free DNA Blood Collection Tu..
PR
02/17BECTON DICKINSON AND : U.S. Patents Awarded to Inventors in Colorado (Feb. 17)
AQ
02/17BECTON DICKINSON AND : U.S. Patents Awarded to Inventors in Utah (Feb. 17)
AQ
02/16BECTON DICKINSON AND : J-- Becton Dickinson Fascanto service agreement
AQ
02/16BECTON, DICKINSON AND COMPANY (NYSE : BDX) Files An 8-K Completion of Acquisitio..
AQ
02/15BECTON DICKINSON AND : FDA Approves New HPV Test that Detects and Identifies HPV..
AQ
02/15BECTON DICKINSON AND : BD Completes Asset Divestitures to Merit Medical
PR
02/13BECTON DICKINSON AND : FDA Approves New HPV Test that Detects and Identifies HPV..
PU
More news
News from SeekingAlpha
02/14Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q4 .. 
02/13FDA OKs BD's new HPV assay 
02/06Becton, Dickinson & Co. (BDX) Q1 2018 Results - Earnings Call Transcript 
02/06Becton, Dickinson and Company 2018 Q1 - Results - Earnings Call Slides 
02/06Becton, Dickinson Q1 revenues up 5%; non-GAAP EPS up 6% 
Financials ($)
Sales 2018 15 833 M
EBIT 2018 4 042 M
Net income 2018 2 222 M
Debt 2018 19 067 M
Yield 2018 1,47%
P/E ratio 2018 34,23
P/E ratio 2019 21,13
EV / Sales 2018 4,88x
EV / Sales 2019 4,19x
Capitalization 58 227 M
Chart BECTON, DICKINSON AND COMP
Duration : Period :
Becton, Dickinson and Comp Technical Analysis Chart | BDX | US0758871091 | 4-Traders
Technical analysis trends BECTON, DICKINSON AND COMP
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 251 $
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Vincent A. Forlenza Chairman & Chief Executive Officer
Thomas Polen President
Christopher R. Reidy Chief Financial Officer, CAO & EVP-Administration
Richard Pierle Chief Information Officer & Executive VP
Bertram L. Scott Independent Director
Sector and Competitors